This test is most useful if any of these apply to you.
A high urine carnosine result can follow a recent meat meal or supplement. Low or undetectable results also occur in healthy people. Researchers are studying how urinary carnosine relates to kidney function and metabolism, but its value for predicting disease or guiding preventive treatment remains unproven.
For prevention and longevity, this is an exploratory biomarker with no validated health target. Measuring urinary carnosine also has a clinical role within an assessment for rare metabolic disorders. Those two uses require different interpretations.
Carnosine consists of beta-alanine and histidine joined together. Your body makes it, and food supplies it too. Most of the body's carnosine is stored in skeletal muscle, where it helps buffer the acidity that develops during intense muscle activity.
Laboratory experiments also show that carnosine binds certain metals and reacts with potentially damaging products of fat breakdown. One of those products is acrolein. Its reaction with carnosine produces carnosine-propanal, which can then become carnosine-propanol. Both have been detected in human urine. They are separate molecules from the intact carnosine measured by this test.
Carnosinase-1 is an enzyme that breaks carnosine into its two component amino acids. Its activity makes intact carnosine difficult to measure in plasma, and breakdown can continue after blood collection. Carnosine inside red blood cells is a different pool that is partly protected from this enzyme.
This measurement quantifies intact carnosine in urine using liquid chromatography with tandem mass spectrometry, or LC-MS/MS. The method separates compounds and identifies them through characteristic molecular signals. Urinary excretion depends on recent intake, breakdown by enzymes, tissue handling, and kidney handling.
Urine results are commonly expressed relative to creatinine to account for differences in dilution. Creatinine is a waste product generated largely by muscle. This adjustment helps compare samples, but it does not remove every source of variation.
Urine and muscle measurements are not interchangeable. A study of 31 healthy volunteers had paired blood and urine measurements for 29 people. Urinary carnosine was associated with red blood cell carnosine after adjustment for demographic factors and diet. Neither measurement was associated with muscle carnosine measured by magnetic resonance spectroscopy. The small sample and variability of the muscle measurements limit how broadly that finding can be applied.
A study of 703 kidney transplant recipients used 24-hour urine collections to examine carnosine and carnosinase-1. About two thirds of recipients had carnosine below the assay's detection limit, compared with 37% of healthy controls. These percentages depend on the assay's sensitivity and should not be treated as universal detection rates.
The prospective finding concerned carnosinase-1, the separate enzyme measurement. Over a median of 5.3 years, each doubling of its daily urinary excretion was associated with about 24% higher risk of transplant failure after adjustment for age, sex, body size, kidney filtration, and urine protein. The association also persisted in models adding other potential confounders.
This study does not establish that low urinary carnosine predicts transplant failure or that a falling result detects early kidney disease. Its findings from transplant recipients also cannot be assumed to apply to otherwise healthy adults.
Most evidence connecting urinary carnosine with cardiovascular or metabolic health comes from studies that measured the urine marker and health characteristics at the same time. These studies can identify associations, but they cannot establish which came first.
In a study of adults with varying cardiovascular risk, lower urinary carnosine was associated with hypertension and heart failure before adjustment. After adjustment for demographic factors, smoking, and medication use, higher intact carnosine was associated with diabetes. Associations with HDL cholesterol persisted for the separate acrolein-bound compounds, not for intact carnosine. Carnosine-propanol also remained associated with heart failure.
An exploratory study of 138 adults found that higher urinary carnosine was associated with lower HDL cholesterol, lower serum folate, and higher homocysteine after adjustment. That study screened many urine chemicals together and used their relative signals. It did not establish clinical decision thresholds for this quantitative test.
These findings do not establish a single healthy direction for urinary carnosine. A high result cannot distinguish recent intake from altered metabolism, and a low result does not establish kidney dysfunction. Using the result to diagnose diabetes, nutrient deficiency, muscle injury, or cardiovascular disease goes beyond the evidence.
Carnosinemia is a rare disorder associated with deficient serum carnosinase activity and increased carnosine in blood and urine. It has been reported in families, but the genetic findings and relationship between enzyme deficiency and symptoms are not consistently established across cases.
Published cases include people with developmental delay, seizures, low muscle tone, or problems with coordination, as well as people without obvious symptoms. A high urine result alone cannot establish this diagnosis or explain neurological symptoms.
A change can reflect altered intake or excretion without indicating a change in disease risk. Consistent collection conditions make comparisons easier, but research has not established a change that reliably signals improving or worsening health. A personal trend therefore remains descriptive unless it is being used within a specific metabolic evaluation or research protocol.
Carnosine is best interpreted alongside these tests.
Carnosine is included in these pre-built panels.
A comprehensive at-home nutritional and metabolic assessment that analyzes key biomarkers to reveal functional nutrient needs and imbalances.